Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. (BNXTF) generates news centered on its work in next-generation drug delivery technologies, particularly sublingual thin films for autoimmune and neurological diseases. Many recent announcements focus on BNT23001, the company’s proprietary sublingual thin-film formulation of cladribine for multiple sclerosis (MS), and on efforts to address pill-swallowing difficulties (dysphagia) with rapid-dissolving “melt-in-your-mouth” dosage forms.
Investors and observers following BNXTF news will find updates on preclinical and bioequivalence studies, including small- and large-mass animal studies designed to define dosing parameters ahead of planned human comparative bioequivalence trials. Company releases also cover intellectual property milestones, such as patent grants and “intention to grant” notifications from the Eurasian Patent Organization and the European Patent Office, as well as a Track One priority patent filing with the U.S. Patent and Trademark Office.
News items further highlight collaboration and pipeline development, including a letter agreement with a European-based chemotherapy company to co-develop a sublingual formulation for oncology and immunosuppressant treatments. Additional disclosures touch on corporate and shareholder matters, such as annual general meeting logistics and investor relations activities.
By reviewing the BNXTF news feed, readers can track how BioNxt advances its sublingual thin-film platform, expands its patent coverage in major pharmaceutical markets, and positions its drug delivery technologies within therapeutic areas like multiple sclerosis, autoimmune conditions, and oncology-related immunosuppression.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioNxt Solutions Inc. (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) announced a significant development by securing a contract with an international pharmaceutical company for the development and manufacturing of an oral dissolvable pharmaceutical product. The contract includes product development, technical sample manufacturing, and stability testing. CEO Hugh Rogers emphasized that this contract marks the second agreement within a year, highlighting the potential for growth in contract work. BioNxt's subsidiary, Vektor Pharma TF GmbH, is known for innovative drug delivery systems, which align with the growing pharmaceutical drug delivery market projected to reach $2,047 billion by 2030. The company is focused on regulatory approval and commercialization of medical products in Europe.
BioNxt Solutions has acquired advanced coating and cutting equipment to enhance its commercial manufacturing capacity at the Vektor Pharma facility in Baden-Württemberg, Germany. This CE certified equipment will enable the production of oral dissolvable (ODF) and transdermal (TDS) drug formulations, as well as ODF biosensor products. The investment aligns with BioNxt's strategy for 2023, focusing on commercialization and contract development opportunities. The fully automated machines will assist in creating pivotal trial materials and final products. BioNxt aims to capitalize on the growing global drug delivery market, projected to exceed USD 2,047 billion by 2030.